Trial · NCT06291038
Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability
Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent ef
- Status
- Recruiting
- Sponsor
- University Hospital, Rouen
- Study type
- Interventional
- Phase
- No phase
- Enrollment
- 60 participants (planned)
- Start
- Oct 3, 2024
- Primary completion
- Mar 1, 2029
- Conditions
- Irritable Bowel Syndrome
Summary
Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high. One of the functional abnormalities described during IBS is increased intestinal permeability. This increase in intestinal permeability is primarily present in the diarrheal subtype (IBS-D) and can be measured using the lactulose/mannitol test.
Interventions
- • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks Dietary supplement
- • Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks. Dietary supplement
Locations
1 country: France.
| Facility | City | Country |
|---|---|---|
| Chu Amiens | Amiens | France |
| CHU CAEN | Caen | France |
| Ch Le Havre | Le Havre | France |
| Chu Rouen | Rouen | France |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.